Welcome to the Working Group on New TB Drugs Blog
News from the 21st Stop TB Partnership Coordinating Board Meeting, Bangkok
he 21st Stop TB Partnership Coordinating Board retreat and meeting officially started in Bangkok, Thailand, on Sunday, January 29th with the official opening ceremony held yesterday January 30th. Included are some exciting news from the meeting courtesy of Mark Harrington, Executive Director of the Treatment Action Group (TAG).
Posted in Faces of TB, TB Prevention and Control Strategies, Video, Voices from the Fight to Stop Tuberculosis
Kick TB Campaign: Scoring Big in South Africa and Beyond
The Kick TB Campaign is a unique project that uses the World’s most popular sport to educate and engage young people in the effort to stop the spread of tuberculosis (TB).
TB R&D Weekly Update: Early bactericidal activity of OPC-67683
This week, we review a recent article published in the July issue of IJTLD on the TB drug candidate OPC-67683 whose new generic name is delamanid. Diacon, et al., present data showing that delamanid is safe, well-tolerated with significant early bactericidal activity. Links to additional TB R&D news is included.
Posted in TB Pediatrics, TB Treatment, Video, Voices from the Fight to Stop Tuberculosis
Interview with Dr. Mark Cotton – Part Two
Dr. Mark Cotton is Director of Children’s Infectious Diseases Clinical Research Unit (KID-CRU) at University of Stellenbosch in Cape Town, South Africa. Pediatric TB has emerged as a broad priority only in more recent years, though the University of Stellenbosch / Tygerberg Hospital team has been focusing on it for more than 20 years. This is part two of our interview with him.
Posted in TB Drug Development, Voices from the Fight to Stop Tuberculosis, WGND Podcast Series
TB R&D Weekly Update: Podcast Interview with Dr. Bernard Fourie
The WGND had the opportunity to interview Dr. Bernard Fourie who is head of Medicine in Need-South Africa (MEND-SA).retoria, South Africa. In the interview, we discuss the ongoing projects at the Drug Research Laboratory at MEND-SA, a research and development center with the mission to developing and applying innovative approaches to the formulation and optimization of existing drugs for the treatment of tuberculosis. Additional links to TB R&D News are included.
Posted in TB Pediatrics, TB Treatment, Video, Voices from the Fight to Stop Tuberculosis
Interview with Dr. Mark Cotton – Part One
Dr. Mark Cotton is Director of Children’s Infectious Diseases Clinical Research Unit (KID-CRU) at University of Stellenbosch in Cape Town, South Africa. Pediatric TB has emerged as a broad priority only in more recent years, though the University of Stellenbosch / Tygerberg Hospital team has been focusing on it for more than 20 years.
TB R&D Weekly Update: Combined Isoniazid and Antiretroviral Therapy Protects HIV-infected Children
In this week’s TB R&D update, the focus is on pediatrics and tuberculosis with several studies published on the subject. Frigati, et al., wanted to determine if isoniazid preventive therapy (IPT) combine with antiretroviral therapy (ART) would reduce TB in HIV-infected children. The article is published online ahead of print this month in Thorax and is entitled “The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting.” Also, links to additional news in TB R&D are included.
Stop TB Partnership’s Coordinating Board Meets in DC
Today was the opening of the 2-day Stop TB Partnership’s Coordinating Board (CB) meeting in Washington, D.C. which included welcoming remarks by Dr. Rajiv Shah (Administrator, USAID), Ms. Lois Quam (Executive Director, GHI), and Dr. Howard Koh (Assistant Secretary, U.S. Depart. of HHS).
Interview with Dr. Anneke Hesseling – Part Three
An interview with Dr. Anneke Hesseling, the Director of the Paediatric TB Research Program at the Desmond Tutu TB Centre at Stellenbosch University in Cape Town, South Africa.
Interview with Dr. Anneke Hesseling – Part Two
An interview with Dr. Anneke Hesseling, the Director of the Paediatric TB Research Program at the Desmond Tutu TB Centre at Stellenbosch University in Cape Town, South Africa.
-
Toppix TB News- Editorial: Lives at risk if the U.S. shortchanges Global Fund 4 Feb 2012
- Multidrug-Resistant Tuberculosis - Update 3 Feb 2012
- Multidrug-Resistant Tuberculosis - Update 3 Feb 2012
- WHO says TB in Russia displays highest known drug resistance 3 Feb 2012
- Media outlets examine Global Fund's future as it enters second decade 3 Feb 2012
